VACC vs. BTAI, BRNS, QTTB, CMRX, MRNS, SPRO, ONCY, CNTB, PRPH, and MIST
Should you be buying Vaccitech stock or one of its competitors? The main competitors of Vaccitech include BioXcel Therapeutics (BTAI), Barinthus Biotherapeutics (BRNS), Q32 Bio (QTTB), Chimerix (CMRX), Marinus Pharmaceuticals (MRNS), Spero Therapeutics (SPRO), Oncolytics Biotech (ONCY), Connect Biopharma (CNTB), ProPhase Labs (PRPH), and Milestone Pharmaceuticals (MIST). These companies are all part of the "pharmaceutical preparations" industry.
Vaccitech (NASDAQ:VACC) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.
26.1% of Vaccitech shares are owned by institutional investors. Comparatively, 30.7% of BioXcel Therapeutics shares are owned by institutional investors. 6.0% of Vaccitech shares are owned by company insiders. Comparatively, 35.8% of BioXcel Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Vaccitech has higher revenue and earnings than BioXcel Therapeutics. Vaccitech is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, BioXcel Therapeutics had 13 more articles in the media than Vaccitech. MarketBeat recorded 14 mentions for BioXcel Therapeutics and 1 mentions for Vaccitech. BioXcel Therapeutics' average media sentiment score of 0.27 beat Vaccitech's score of -0.30 indicating that BioXcel Therapeutics is being referred to more favorably in the news media.
BioXcel Therapeutics received 221 more outperform votes than Vaccitech when rated by MarketBeat users. However, 70.83% of users gave Vaccitech an outperform vote while only 67.23% of users gave BioXcel Therapeutics an outperform vote.
Vaccitech has a beta of -0.4, suggesting that its stock price is 140% less volatile than the S&P 500. Comparatively, BioXcel Therapeutics has a beta of 0.43, suggesting that its stock price is 57% less volatile than the S&P 500.
Vaccitech currently has a consensus target price of $7.63, suggesting a potential upside of 228.66%. BioXcel Therapeutics has a consensus target price of $16.71, suggesting a potential upside of 699.73%. Given BioXcel Therapeutics' higher probable upside, analysts clearly believe BioXcel Therapeutics is more favorable than Vaccitech.
Vaccitech has a net margin of -409.18% compared to BioXcel Therapeutics' net margin of -8,715.72%. Vaccitech's return on equity of -23.41% beat BioXcel Therapeutics' return on equity.
Summary
BioXcel Therapeutics beats Vaccitech on 10 of the 18 factors compared between the two stocks.
Get Vaccitech News Delivered to You Automatically
Sign up to receive the latest news and ratings for VACC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VACC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vaccitech Competitors List
Related Companies and Tools
